Literature DB >> 29293895

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Babafemi O Taiwo1, Vincent C Marconi2, Baiba Berzins1, Carlee B Moser3, Amesika N Nyaku4, Carl J Fichtenbaum5, Constance A Benson6, Timothy Wilkin7, Susan L Koletar8, Jonathan Colasanti2, Edward P Acosta9, Jonathan Z Li10, Paul E Sax11.   

Abstract

Clinical Trials Registration: NCT02263326.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29293895      PMCID： PMC5961309          DOI： 10.1093/cid/cix1131

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

Authors:  José R Arribas; Pierre-Marie Girard; Roland Landman; Judit Pich; Josep Mallolas; María Martínez-Rebollar; Francisco X Zamora; Vicente Estrada; Manuel Crespo; Daniel Podzamczer; Joaquín Portilla; Fernando Dronda; José A Iribarren; Pere Domingo; Federico Pulido; Marta Montero; Hernando Knobel; André Cabié; Laurence Weiss; José M Gatell
Journal:  Lancet Infect Dis       Date:  2015-06-07       Impact factor: 25.071

2.  Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Authors:  Simona Di Giambenedetto; Massimiliano Fabbiani; Eugenia Quiros Roldan; Alessandra Latini; Gabriella D'Ettorre; Andrea Antinori; Antonella Castagna; Giancarlo Orofino; Daniela Francisci; Pierangelo Chinello; Giordano Madeddu; Pierfrancesco Grima; Stefano Rusconi; Massimo Di Pietro; Annalisa Mondi; Nicoletta Ciccarelli; Alberto Borghetti; Emanuele Focà; Manuela Colafigli; Andrea De Luca; Roberto Cauda
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

3.  Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

Authors:  Sidonie Lambert-Niclot; Philippe Flandre; Marc-Antoine Valantin; Gilles Peytavin; Claudine Duvivier; Stephanie Haim-Boukobza; Michele Algarte-Genin; Yazdan Yazdanpanah; Pierre-Marie Girard; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

4.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.

Authors:  Sherene Min; Louis Sloan; Edwin DeJesus; Trevor Hawkins; Lewis McCurdy; Ivy Song; Richard Stroder; Shuguang Chen; Mark Underwood; Tamio Fujiwara; Stephen Piscitelli; Jay Lalezari
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

5.  The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Authors:  Michael P Girouard; Paul E Sax; Robert A Parker; Babafemi Taiwo; Kenneth A Freedberg; Roy M Gulick; Milton C Weinstein; A David Paltiel; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

6.  A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.

Authors:  Chantelle Bennetto-Hood; Glenn Tabolt; Paul Savina; Edward P Acosta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-12-03       Impact factor: 3.205

7.  2014 Update of the drug resistance mutations in HIV-1.

Authors:  Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman
Journal:  Top Antivir Med       Date:  2014 Jun-Jul

8.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321

9.  Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Authors:  Federico Pulido; Esteban Ribera; María Lagarde; Ignacio Pérez-Valero; Rosario Palacios; José A Iribarren; Antoni Payeras; Pere Domingo; José Sanz; Miguel Cervero; Adrián Curran; Francisco J Rodríguez-Gómez; María J Téllez; Pablo Ryan; Pilar Barrufet; Hernando Knobel; Antonio Rivero; Belén Alejos; María Yllescas; José R Arribas
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079
  9 in total
  24 in total

Review 1.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

2.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

3.  Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.

Authors:  Y S Punekar; D Parks; M Joshi; S Kaur; L Evitt; V Chounta; M Radford; D Jha; S Ferrante; S Sharma; J Van Wyk; A de Ruiter
Journal:  HIV Med       Date:  2021-02-02       Impact factor: 3.180

4.  Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.

Authors:  Lauren Greenberg; Lene Ryom; Bastian Neesgaard; Gilles Wandeler; Therese Staub; Martin Gisinger; Michael Skoll; Huldrych F Günthard; Alexandra Scherrer; Cristina Mussini; Colette Smith; Margaret Johnson; Stéphane De Wit; Coca Necsoi; Christian Pradier; Ferdinand Wit; Clara Lehmann; Antonella d'Arminio Monforte; Jose M Miró; Antonella Castagna; Vincenzo Spagnuolo; Anders Sönnerborg; Matthew Law; Jolie Hutchinson; Nikoloz Chkhartishvili; Natalia Bolokadze; Jan-Christian Wasmuth; Christoph Stephan; Vani Vannappagari; Felipe Rogatto; Josep M Llibre; Claudine Duvivier; Jennifer Hoy; Mark Bloch; Heiner C Bucher; Alexandra Calmy; Alain Volny Anne; Annegret Pelchen-Matthews; Jens D Lundgren; Lars Peters; Loveleen Bansi-Matharu; Amanda Mocroft
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

Review 5.  Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.

Authors:  Katya C Corado; Margaret R Caplan; Eric S Daar
Journal:  Drug Des Devel Ther       Date:  2018-11-01       Impact factor: 4.162

Review 6.  Dolutegravir/rilpivirine for the treatment of HIV-1 infection.

Authors:  Ellen Dowers; Francis Zamora; Lydia Aoun Barakat; Onyema Ogbuagu
Journal:  HIV AIDS (Auckl)       Date:  2018-11-02

Review 7.  Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2020-01       Impact factor: 11.431

8.  Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.

Authors:  Sara Gianella; Vincent C Marconi; Baiba Berzins; Constance A Benson; Paul Sax; Carl J Fichtenbaum; Timothy Wilkin; Millie Vargas; Qianqian Deng; Michelli F Oliveira; Carlee Moser; Babafemi O Taiwo
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-15       Impact factor: 3.771

Review 9.  Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Authors:  Romina Quercia; Carlo-Federico Perno; Justin Koteff; Katy Moore; Cynthia McCoig; Marty St Clair; Daniel Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

Review 10.  Two's a Company, Three's a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naïve and Treatment-Experienced Patients Living with HIV-1.

Authors:  Melissa Badowski; Sarah E Pérez; David Silva; Andrea Lee
Journal:  Infect Dis Ther       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.